Extended Duration Nicotine Replacement Therapy and Bupropion in Smokers With Schizophrenia
Status:
Terminated
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
After successfully quitting smoking, smokers with schizophrenia are vulnerable to relapse
shortly after discontinuation of treatment. The purpose of this study was to assess the
feasibility and effectiveness of a 12-month relapse prevention intervention in recently
abstinent smokers with schizophrenia. Subjects participated in a 12-week smoking cessation
phase, where they received nicotine replacement therapy, bupropion SR 150mg bid, and
cognitive behavioral therapy. If, at the end of the 12 weeks, they were able to demonstrate 1
week of abstinence, they continued in the relapse prevention phase of the study, where they
continued to receive nicotine replacement therapy, bupropion SR 150mg bid, and cognitive
behavioral therapy.